Stockreport

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF – Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 – – Novel transdermal formulation [Read more]